advertisement
3.8 Pharmacology (50)
Showing records 1 to 25
Display all abstracts in classification 3.8 Pharmacology
Search within classification 3.8 Pharmacology71452 Targeting Transforming Growth Factor-β Signaling in Primary Open-Angle Glaucoma
Wang J
Journal of Glaucoma 2017; 26: 390-395
71589 The P2X7 receptor links mechanical strain to cytokine IL-6 upregulation and release in neurons and astrocytes
Lu W
Journal of Neurochemistry 2017; 0:
71291 The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast regulates extracellular matrix remodeling
Peng J
Biochemical and Biophysical Research Communications 2017; 484: 474-479
71552 Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro
Stahnke T
PLoS ONE 2017; 12: e0172592
71582 TGFβ2 Induces the Formation of Cross-Linked Actin Networks (CLANs) in Human Trabecular Meshwork Cells Through the Smad and Non-Smad Dependent Pathways
Montecchi-Palmer M
Investigative Ophthalmology and Visual Science 2017; 58: 1288-1295
71490 Retinal Diseases Associated with Oxidative Stress and the Effects of a Free Radical Scavenger (Edaravone)
Masuda T
Oxidative medicine and cellular longevity 2017; 2017: 9208489
71257 Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)
Vicente A
Ophthalmic Research 2017; 57: 201-207
71631 Aquaporin-Targeted Therapeutics: State-of-the-Field
Tradtrantip L
Adv Exp Med Biol 2017; 969: 239-250
71478 In vivo Pharmacological Evaluations of Pilocarpine-Loaded Antioxidant-Functionalized Biodegradable Thermogels in Glaucomatous Rabbits
Chou SF
Scientific reports 2017; 7: 42344
71589 The P2X7 receptor links mechanical strain to cytokine IL-6 upregulation and release in neurons and astrocytes
Albalawi F
Journal of Neurochemistry 2017; 0:
71452 Targeting Transforming Growth Factor-β Signaling in Primary Open-Angle Glaucoma
Harris A
Journal of Glaucoma 2017; 26: 390-395
71552 Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro
Kowtharapu BS
PLoS ONE 2017; 12: e0172592
71257 Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)
Prud'homme S
Ophthalmic Research 2017; 57: 201-207
71631 Aquaporin-Targeted Therapeutics: State-of-the-Field
Jin BJ
Adv Exp Med Biol 2017; 969: 239-250
71478 In vivo Pharmacological Evaluations of Pilocarpine-Loaded Antioxidant-Functionalized Biodegradable Thermogels in Glaucomatous Rabbits
Luo LJ
Scientific reports 2017; 7: 42344
71291 The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast regulates extracellular matrix remodeling
Zhou H
Biochemical and Biophysical Research Communications 2017; 484: 474-479
71582 TGFβ2 Induces the Formation of Cross-Linked Actin Networks (CLANs) in Human Trabecular Meshwork Cells Through the Smad and Non-Smad Dependent Pathways
Bermudez JY
Investigative Ophthalmology and Visual Science 2017; 58: 1288-1295
71490 Retinal Diseases Associated with Oxidative Stress and the Effects of a Free Radical Scavenger (Edaravone)
Shimazawa M
Oxidative medicine and cellular longevity 2017; 2017: 9208489
71452 Targeting Transforming Growth Factor-β Signaling in Primary Open-Angle Glaucoma
Prendes MA
Journal of Glaucoma 2017; 26: 390-395
71257 Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)
Ferreira J
Ophthalmic Research 2017; 57: 201-207
71478 In vivo Pharmacological Evaluations of Pilocarpine-Loaded Antioxidant-Functionalized Biodegradable Thermogels in Glaucomatous Rabbits
Lai JY
Scientific reports 2017; 7: 42344
71490 Retinal Diseases Associated with Oxidative Stress and the Effects of a Free Radical Scavenger (Edaravone)
Hara H
Oxidative medicine and cellular longevity 2017; 2017: 9208489
71552 Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro
Stachs O
PLoS ONE 2017; 12: e0172592
71589 The P2X7 receptor links mechanical strain to cytokine IL-6 upregulation and release in neurons and astrocytes
Beckel JM
Journal of Neurochemistry 2017; 0:
71631 Aquaporin-Targeted Therapeutics: State-of-the-Field
Yao X
Adv Exp Med Biol 2017; 969: 239-250
